Clinical Trial Search

Primary: Change From Baseline in Clinical Administered PTSD Scale (CAPS) Total — -39 units on a scale — p=<.0001

Primary: Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement. — 6.43; -12.53; -19.41; 14.48 Minutes

Primary: Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room — 160; 173 seconds — p=0.77

Primary: Drug's Breakpoint — 1200; 10; 1100; 1200 number of clicks on a mouse

Primary: CPAP Therapy Adherence — 103 participants

Primary: PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAP — 80.4; 83.1 percentage of participants

Primary: Change in Circulating ICAM-1 Shown by Absolute Values at Baseline, Day 28 and Day 56 — 707; 701; 679; 627 nanogram/ml — p=>0.05

Primary: Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase. — 40.1; 53.8 Percentage of…

Primary: Sedative Doses of Fentanyl — 1.09; 1.28 mcg/kg — p=<0.0001

Primary: Two-year All-cause Mortality — 11 percentage of participants

Primary: Subjects Will Demonstrate a Successful Defibrillation Outcome if They Have 2 Successful Defibrillation Shocks With the Research System. — 85.7 percentage of success

Primary: Percentage of Participants on Tocilizumab 6 Months After Treatment Initiation — 93.75 percentage of participants

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 0; 38 participants

Primary: Urinary Incontinence (Prevalence) — 30; 34; 57; 54 participants — p=0.57

Primary: Number of Participants With Version of Fetal Breech Position to Cephalic Position up to 4 Weeks After Treatment — 34; 25; 34; 25 participants — p=0.48